Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-102

It will be a lot clearer shortly mate. I’m sure the company has had ample discussions with various big pharma already.. phase 2 is well under way with a lot of diversified opportunities to come.

If results do go as planned I have no doubt this is a Unicorn in the making with every major pharmaceutical wanting a slice. The dilution is not ideal of course .. but it gets us to where we need to be and provides cash flow certainty.

In hindsight the raise was done at the right time with the current climate being a difficult one for equity raises.

Management has done it all before. They are one of the best teams you could have when it comes to FDA submissions.

Yes it’s frustrating but it could be extremely life changing!

Cheers.